Fetroja (cefiderocol) / Shionogi  >>  Phase 3
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Fetroja (cefiderocol) / Shionogi
APEKS-NP, NCT03032380 / 2016-003020-23: Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens

Completed
3
300
Europe, Canada, Japan, US, RoW
Cefiderocol, S-649266, Meropenem, Merrem®, Linezolid, Zyvox®
Shionogi
Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP), Ventilator Associated Pneumonia (VAP)
02/19
04/19
CREDIBLE - CR, NCT02714595 / 2015-004703-23: Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens

Completed
3
152
Europe, Japan, US, RoW
Cefiderocol, S-649266, Fetroja ®, Best Available Therapy
Shionogi
Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI), Hospital Acquired Pneumonia (HAP), Complicated Urinary Tract Infection (cUTI), Sepsis, Ventilator Associated Pneumonia (VAP)
04/19
04/19

Download Options